Slide 1: Genetic Technologies Limited
ae GENETIC TECHNOLOGIES LIMITED (NASDAQ: GENE, ASX:GTG) January 2011 % 3,2 . _ S
Slide 2: Forward Looking Statements
echnologies Forward Looking Statements ee. This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achieveme
Slide 3: Genetic Technologies Ltd (NASDAQ:GENE, ASX:GTG)
‘genet technologies Genetic Technologies Ltd (NASDAQ:GENE, ASX:GTG) br = Substantial near-term global growth opportunities in cancer diagnostics = Existing annuities & growing revenues from non-coding DNA IP out-licensing = Increasing substantially through US IP assertion suit = Successes in Europe
Slide 4: Investment Snapshot
Investment Snapshot ve oenetctectrooyes GTG to soon launch world’s first validated test for non- familial breast cancer globally: = BREVAGen™ has attractive CoGS and rapid payback = Purchased all key assets from Perlegen Inc. incl. BREVAGen™ for less than $1.5m during financial crisis, Perlegen tota
Slide 5: BREVAGen™ — Launch This Quarter
BREVAGen™ — Launch This Quarter Novel, validated non-familial breast cancer risk test: Preparing for US launch Q1 2011 Oct10 JNCI validation study High profile KOLs engaged Large validation populations Substantial global opportunity US reimbursement strategy in place
Slide 6: BREVAGen™ — What it Means Clinically
‘genet technologies BREVAGen™ — What it Means Clinically ve = Genetic breast cancer prognostic test = Test combines population risk factors (Gail Score) with genetic risk factors (7 SNP biomarkers) to give integrated individual breast cancer risk assessment = BREVAGen™ is first fully peer reviewed v
Slide 7: BREVAGen™ Fits Into Existing ASCO and ACS Breast Cancer Guidelines
BREVAGen™ — Fits Into Existing ASCO and ACS Breast Cancer Guidelines ESNet Invasive breast cancer ~ Avoid unnecessary Rx » Cancer 20% ~ ) (Abnormal 6596 F apevacen > Annual mammograms ) Normal 15% vv ‘SERM Rx eg Tamoxifen Normal Tissue 1.6m breast biopsy patients pa (USA) >1m patients at indetermina
Slide 8: Published Validation Paper
Published Validation Paper ee. = Published, Journal of the National Cancer Institute Oct 2010 = First SNP panel prognostic test to secure a pivotal paper in a top tier journal “Combining validated common genetic risk factors with clinical risk factors resulted in modest improvement in classification
Slide 9: Qualified Market Opportunity
echnologies Qualified Market Opportunity ee. = US market for existing breast cancer molecular diagnostics ~$690m* in 2006 & grown “18% CAGR since = Referenced by = BRACAnalysis (Myriad Inc) sales ~S260m = OncotypeDx (Genomics Health) *$160m = Other players (Genzyme, Clarient °, etc) made up the bala
Slide 10: BREVAGen™ SNP Panel
BREVAGen™ SNP Panel Large Discovery & Validation Data Sets SNP Discovery Stage 1: Genotyped 266,722 SNPs in 440 “High-Risk” Breast Cancer Cases and 400 Controls Stage 2: Genotyped top 12,711 SNPs in 3990 Invasive Breast Cancer Cases and 3916 Control Stage 3: Top 30 SNPs tested in carcinoma in s 973
Slide 11: Compelling Pharmacoeconomics
Compelling Pharmacoeconomics hh a Presented as a poster ASCO 2010 (Chicago), Archimedes Group + GTG Intervention BREVAGen™ ee vs. Gail Alone* “eas $14,300 $3,900 BREVAGen™ vs. Gail Alone* 50-59 $17,600 $3,800 BREVAGen™ vs. Gail Alone* 60-69 $72,100 $7,500 Standard of Care Annual Mammography only vs.
Slide 12: Genetics of Breast Cancer Risk
Genetics of Breast Cancer Risk oe. Genes can either be detected as = Mutations (BRCA1 & BRCA2) or = Single nucleotide polymorphisms, indicating a higher with cancer risk = To date; BRCA testing has been well utilized yet the vast majority of breast cancer occurs without an . . . . . Familial indicat
Slide 13: Target Patient Groups
Target Patient Groups = Three target markets have been identified: 1. _BRCA negative patients * 80-90% of BRCA results are negative 2. Breast Biopsy patients ADH! * Patients undergoing are known ALA to have increased breast cancer ee risk Non-cancerous 3. Women over 35 who have a icra family history
Slide 14: Stages of Sales Channel Growth
Stages of Sales Channel Growth we = Initial target market Year 1-3 = MD’s with high numbers of BRCA patient tests = 80-90% of BRCA results are negative = 1,521 High Value MD/OBGYN’s identified = Second target market Year 2-4 = MD’s in Breast Biopsy procedures = 1m indeterminate biopsy patients per a
Slide 15: Sales and Marketing Deployment
Sales and Marketing Deployment we sale Training RM offers Clase Extended Bee] 40 ant on | bate Monn# ess Glo Ceo Marketing Director Eabion region (ta, Region Manager Manes Managers CLIAApproval: Jan, 2011 pproval: Jan, Planned | Revenue Goals May, 2011 Launch
Slide 16: Business Overview — Licensing
technologies Business Overview — Licensing bor = Non-coding DNA patent estate is one of GTG’s core assets = $60mt+ licensing revenue received to date = Ongoing annuity stream of $9.2m to end of ‘762 patent in 2015 = Foundational patent families protecting the use of non-coding DNA ui 179, “Intron Se
Slide 17: Licensees
Licensees 50+ licensees across range of industries - Many have delivered synergistic business opportunities Agriculture Medical Instruments nonsanro [gl gee | SEQUENOM syngenta Pat) ae Applied INGS ne S 3 oe BON GBD Plizer énimat Health &LabCorp ThermoFisher’ SS SCIENTIFIC (6) Pal & PIONEER. MYRIAD.
Slide 18: Patent Assertion Program
Patent Assertion Program ee. technologies Parties joined suit #1: = Partnership with Sheridan Ross PC, a full ¥ Beckman Coulter service intellectual property law firm based in v Gen-probe Colorado ¥ Interleukin Genetics = |P assertion program activated & first suit Y Molecular filed in US District C
Slide 19: Regulatory & Reimbursement
Regulatory & Reimbursement ir technologies = CLIA dossiers submitted — first Australian facilities to service US market = Test validation complete with new substrate platform = Premier Source (San Mateo, CA) engaged to provide payer management services & reimbursement strategy support : commencing w
Slide 20: Prominent KOLs Involved
Prominent KOLs Involved Kevin S Hughes, M.D., FACS Surgical Director, Breast Screening Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts Allison W. Kurian, M.D., M.Sc. Assistant Professor of Medicine (Oncology) Stanford University School of Medicine Richard Frieder, MD Associate
Slide 21: Competitors
Competitors we technologies = DeCode (Iceland) = Launched in October 2008 by deCODE Genetics, no validation = deCODE Breast Cancer test assesses a woman’s risk based on 7 common SNPs, ordered only via MDs. Price = $1,650 = Emerged from Chapter 11 in April 2010 as a private company (Saga Investments)
Slide 22: Oncology Focus
technologies Oncology Focus we The WW MDx Market ($Bn) = New technologies driving * not including Industrial and Research areas targeted interventions & 12,0 $050 Aan .9 Bn extending lives 4 . . | 100 | CAGR 17.6% = Molecular diagnosis of cancer is ‘ 2007-1014 most attractive segment of the a0 Fay 0
Slide 23: Cancer Management Strategy
Cancer Management Strategy DIFFERENTIAL mcs oom ee a igll ff \ Am | at risk Is there a chance Do | have cancer ‘Has my cancer dat, “eite Ela Meee! ere) ec ae a 2005 launch Planned Q1 2011 launch Feb'10 launch: = A BREVAGen” es - Unique portfolio approach Oe. THERAPY SELECTION WEA, sunveuance wet ] H
Slide 24: Pacific Rim Business
Pacific Rim Business = Contracted provider to NSW Police Force for volume crime forensic testing = 50+% market share Aust/NZ paternity testing = Exclusive provider genetic testing most PacRim canine breed clubs " Leading contracted provider of paternity tests to lawyers, Dept of Immigration, Legal A
Slide 25: Financial Trends (by quarter)
Financial Trends (by quarter) = Rising revenues = Better cost control = Trend to positive cash flows Genetic Technologies Limited Gross revenues by quarter ‘Operations micensing = Other Ww Genetic Technologies Limited Net operating cashflows by quarter 015 1 sifalll Jun.2009Sep.2009 Dec. 2009 Mar.20
Slide 26: Financial Snapshot Dec 2010
Financial Snapshot Dec 2010 ee. Financials (year to Dec31) Share Register (AUD millions) 2010 2009 =» Shares outstanding 404.6m Operations revenue 5.23 5.38 Top 20 shareholders 76% Licensing revenue 13.62 6.01 Total shareholders 2,850 Net income / (loss) (2.32) (7.85) = Qptions outstanding (*) 14.3m
Slide 27: Summary
Summary ir genetic technologies = GTG to soon launch first validated test for non-familial breast cancer globally = BREVAGen™ has attractive CoGS, ROI & rapid payback = Target market is global, characterized and large = Launch in US first quarter 2011 = GTG has a sound established business with reli
Slide 28: Contact Details
Contact Details we Dr Paul D R MacLeman CEO Genetic Technologies Limited Direct Phone +613 8412 7025 Cell +61 419 401 445 (Aust.) (980) 253 4340 (US) Email paul.macleman@gtglabs.com 29